智通财经APP讯,沛嘉医疗-B(09996)公布,用于治疗重度主动脉瓣反流的 TrilogyTM经导管心脏瓣膜(THV)系统于中国台湾的首两例植入成功完成。
TrilogyTM THV系统为拥有独占许可并获得CE标志认证的经导管主动脉瓣置换产品,适用于心脏团队(包括心脏外科医生)判定为外科主动脉瓣置换手术风险高或较高的症状性重度主动脉瓣反流或症状性重度主动脉瓣狭窄患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.